This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...

(RTTNews) - Eli Lilly and Company (LLY) on Monday said its new formulation of Taltz (ixekizumab), which was approved by the FDA in May this year, is being made available across the U.S. The company ...